【IQVIA-2025研报】艾昆纬-为中型制药公司提供综合药物开发、监管战略和人工智能创新（英）.pdfVIP

WhitePaper

EmpoweringMid-sizePharma

CompanieswithIntegrated

DrugDevelopment,Regulatory

Strategy,andAIInnovation

MICHELLEGYZEN,SeniorDirectorofStrategicRegulatorySolutions,IQVIA

BRIANHEALEY,GlobalHeadofDrugDevelopmentandRegulatoryStrategy,IQVIA

CLAIREDAVIES,SeniorDirector,RegulatoryAffairs,IQVIA

Tableofcontents

Introduction1

Theconsultative,end-to-endCROmodel2

Arobustregulatoryapproach3

ThestrategicroleofAIinmid-sizepharmacompanies4

AnIQVIAcustomersuccessstory4

Secureyourcompetitiveadvantage4

Abouttheauthors5

AboutIQVIA5

Introduction

Mid-sizepharmacompaniessitatadistinctintersectioninthecurrent

pharmaceuticallandscape.Whiletheirteamshavetheagilitytoinnovatequickly,

theymaylackthescale,infrastructure,andresourcesoflargercompanies,

creatingbothriskandopportunity.Withoutrobustsupport,promisingassets

canstall,compliancegapscanemerge,andvaluablemarketopportunitieswill

fallbythewayside.However,withtherightCROpartner,theseorganizations

canconverthighpotentialintospeed-to-market.

Thoughmanymid-sizeorganizationsmayavoid

theCROrouteforfearofhighcosts,lossofcontrol,

orinsufficientsupport,astrategicpartnershipcan

beactivatedtomitigatetheseconcernsandtransformAconsultative,tech-enabledCRO

potentialchallengesintoadvantages.Aconsultative,canhelpsmalltomid-sizepharma

tech-enabledCR